Recent clinical and preclinical studies have highlighted the remarkable efficacy of CAR-T cells in targeting HCC, with several molecules, including GPC3, AFP, c-Met, and CD133, emerging as promising targets for immunotherapy in HCC (9). This evidence concerns the gene AFP and hepatocellular carcinoma.